| Lung Non-Small Cell Carcinoma13 |
|---|
| ROS1 G2032R | Crizotinib | Predictive | B | Supports Resistance | 4 | submitted | EID7684In a retrospective study, authors identified 16 ROS1 fusion-positive lung cancer patients who underwent a total of 17 repeat biopsies following disease progression on crizotinib
ROS1 resistance mutat… (full text at CIViC) PMID 29333528 · Gainor et al., 2017 · Open in CIViC | civic |
| ROS1 G2032R | Crizotinib | Predictive | C | Supports Resistance | — | submitted | EID4614In a phase 1 study (NCT00585195), a stage IIIA pulmonary adenocarcinoma patient with acquired crizotinib resistance harbored a CD74-ROS1 gene rearrangement (a known sensitizing alteration to crizotini… (full text at CIViC) PMID 25688157 · Song et al., 2015 · Open in CIViC | civic |
| ROS1 G2032R | Crizotinib | Predictive | D | Supports Resistance | — | submitted | EID4615In an in vitro study, a Ba/F3 cell line expressing CD74-ROS1 fusion (a known sensitizing alteration to crizotinib) and a ROS1 G2032R co-mutation demonstrated resistance to crizotinib treatment (1,192 … (full text at CIViC) PMID 26372962 · Davare et al., 2015 · Open in CIViC | civic |
| ROS1 G2032R | Crizotinib | Predictive | D | Supports Resistance | — | submitted | EID4616In an in vitro study, a Ba/F3 cell line expressing a G2032R mutation in the ROS1 portion of the EZR-ROS1 fusion protein was associated with resistance to crizotinib treatment (IC50: 1287 nM), as comp… (full text at CIViC) PMID 27401242 · Facchinetti et al., 2016 · Open in CIViC | civic |
| ROS1 G2032R | Repotrectinib | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID7687A patient with ROS1 fusion-positive NSCLC was treated with crizotinib. After tumor progression, a repeat biopsy revealed ROS1 G2032R mutation.
The patient subsequently enrolled in the phase I repotrec… (full text at CIViC) PMID 30093503 · Drilon et al., 2018 · Open in CIViC | civic |
| ROS1 G2032R AND CD74::ROS1 Fusion | Cabozantinib | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1101Cabozantinib was assessed in the CD74-ROS1-mutant Ba/F3 cells and crizotinib-resistant patient-derived cancer cells (MGH047) harboring G2032R-mutated CD74-ROS1. It effectively inhibited the survival o… (full text at CIViC) PMID 25351743 · Katayama et al., 2015 · Open in CIViC | civic |
| ROS1 G2032R AND CD74::ROS1 Fusion | Crizotinib | Predictive | C | Supports Resistance | 3 | accepted | EID1254ROS1 kinase domain mutations were assessed in two patients with stage IIIa/IV pulmonary adenocarcinoma and a cell line. The ROS1 G2032R mutation was identified in a crizotinib-resistant tumor from one… (full text at CIViC) PMID 25688157 · Song et al., 2015 · Open in CIViC | civic |
| ROS1 G2032R AND CD74::ROS1 Fusion | AZD3463 + Brigatinib + Ceritinib + CrizotinibSubstitutes | Predictive | D | Supports Resistance | 3 | accepted | EID1250Preclinical study analyzing the efficacy of dual ROS1/ALK and more specific ROS1 inhibitors on cell lines (Ba/F3) expressing CD74-ROS1 with and without the G2032R mutation. Selective ROS1 inhibitors r… (full text at CIViC) PMID 26372962 · Davare et al., 2015 · Open in CIViC | civic |
| ROS1 G2032R AND CD74::ROS1 Fusion | Foretinib | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID1255Ba/F3 cells expressing CD74–ROS1 G2032R showed resistance to crizotinib, compared with those expressing wild-type CD74–ROS1 (~128 fold higher IC50); however, showed relative sensitivity to foretinib (… (full text at CIViC) PMID 25688157 · Song et al., 2015 · Open in CIViC | civic |
| ROS1 G2032R AND CD74::ROS1 Fusion | Cabozantinib + ForetinibSubstitutes | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1249Preclinical study analyzing the efficacy of dual ROS1/ALK and more specific ROS1 inhibitors on cell lines (Ba/F3) expressing CD74-ROS1 with and without the G2032R mutation. Selective ROS1 inhibitors r… (full text at CIViC) PMID 26372962 · Davare et al., 2015 · Open in CIViC | civic |
| ROS1 G2032R AND v::ROS1 Fusion | Lorlatinib | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1251Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. PF-06463922 showed inhibition of kinase activity, cell viability and tumor growth in wild-type, G2032R and L2026M muta… (full text at CIViC) PMID 25733882 · Zou et al., 2015 · Open in CIViC | civic |
| ROS1 G2032R AND v::ROS1 Fusion | Repotrectinib | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID12022In a phase 1-2 trial (NCT03093116), the ROS1/ALK/NTRK inhibitor repotrectinib demonstrated efficacy in NSCLC with ROS1 fusions. In the 56 patients who had previously received one ROS1 tyrosine kinase… (full text at CIViC) PMID 38197815 · Drilon et al., 2024 · Open in CIViC | civic |
| ROS1 G2032R AND v::ROS1 Fusion | Taletrectinib | Predictive | B | Supports Sensitivity Response | 2 | submitted | EID12236The TRUST-I study (NCT04395677) was a phase II, multicenter, single-arm, open-label trial conducted in China to evaluate taletrectinib for ROS1 fusion-positive, locally advanced, or metastatic non-sma… (full text at CIViC) PMID 38822758 · Li et al., 2024 · Open in CIViC | civic |